312 related articles for article (PubMed ID: 31227936)
41. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
[TBL] [Abstract][Full Text] [Related]
42. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Geyer HL; Mesa RA
Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
[TBL] [Abstract][Full Text] [Related]
43. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
Quintás-Cardama A; Verstovsek S
Clin Cancer Res; 2013 Apr; 19(8):1933-40. PubMed ID: 23406773
[TBL] [Abstract][Full Text] [Related]
44. Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms.
Patel PR; Senyuk V; Rodriguez NS; Oh AL; Bonetti E; Mahmud D; Barosi G; Mahmud N; Rondelli D
Biol Blood Marrow Transplant; 2019 May; 25(5):855-860. PubMed ID: 30615982
[TBL] [Abstract][Full Text] [Related]
45. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.
Nieborowska-Skorska M; Maifrede S; Dasgupta Y; Sullivan K; Flis S; Le BV; Solecka M; Belyaeva EA; Kubovcakova L; Nawrocki M; Kirschner M; Zhao H; Prchal JT; Piwocka K; Moliterno AR; Wasik M; Koschmieder S; Green TR; Skoda RC; Skorski T
Blood; 2017 Dec; 130(26):2848-2859. PubMed ID: 29042365
[TBL] [Abstract][Full Text] [Related]
46. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
Winter PS; Sarosiek KA; Lin KH; Meggendorfer M; Schnittger S; Letai A; Wood KC
Sci Signal; 2014 Dec; 7(357):ra122. PubMed ID: 25538080
[TBL] [Abstract][Full Text] [Related]
47. Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms.
Takei H; Coelho-Silva JL; Tavares Leal C; Queiroz Arantes Rocha A; Mantello Bianco T; Welner RS; Mishima Y; Kobayashi IS; Mullally A; Lima K; Machado-Neto JA; Kobayashi SS; Lobo de Figueiredo-Pontes L
Cancer Sci; 2022 Feb; 113(2):597-608. PubMed ID: 34808021
[TBL] [Abstract][Full Text] [Related]
48. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
de Oliveira MB; Fook-Alves VL; Eugenio AIP; Fernando RC; Sanson LFG; de Carvalho MF; Braga WMT; Davies FE; Colleoni GWB
Cancer Lett; 2017 Sep; 403():206-215. PubMed ID: 28645562
[TBL] [Abstract][Full Text] [Related]
49. Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages.
Febvre-James M; Lecureur V; Augagneur Y; Mayati A; Fardel O
Int Immunopharmacol; 2018 Jan; 54():354-365. PubMed ID: 29202299
[TBL] [Abstract][Full Text] [Related]
50. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.
Rampal R; Al-Shahrour F; Abdel-Wahab O; Patel JP; Brunel JP; Mermel CH; Bass AJ; Pretz J; Ahn J; Hricik T; Kilpivaara O; Wadleigh M; Busque L; Gilliland DG; Golub TR; Ebert BL; Levine RL
Blood; 2014 May; 123(22):e123-33. PubMed ID: 24740812
[TBL] [Abstract][Full Text] [Related]
51. Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2
Courdy C; Platteeuw L; Ducau C; De Araujo I; Boet E; Sahal A; Saland E; Edmond V; Tavitian S; Bertoli S; Cougoul P; Granat F; Poillet L; Marty C; Plo I; Sarry JE; Manenti S; Mansat-De Mas V; Joffre C
Blood Cancer J; 2023 Jul; 13(1):106. PubMed ID: 37423955
[TBL] [Abstract][Full Text] [Related]
52. JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions.
Beckman JD; DaSilva A; Aronovich E; Nguyen A; Nguyen J; Hargis G; Reynolds D; Vercellotti GM; Betts B; Wood DK
J Thromb Haemost; 2023 May; 21(5):1366-1380. PubMed ID: 36738826
[TBL] [Abstract][Full Text] [Related]
53. Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.
Austin RJ; Straube J; Bruedigam C; Pali G; Jacquelin S; Vu T; Green J; Gräsel J; Lansink L; Cooper L; Lee SJ; Chen NT; Lee CW; Haque A; Heidel FH; D'Andrea R; Hill GR; Mullally A; Milsom MD; Bywater M; Lane SW
Leukemia; 2020 Apr; 34(4):1075-1089. PubMed ID: 31732720
[TBL] [Abstract][Full Text] [Related]
54. Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells.
Cheng Z; Fu J; Liu G; Zhang L; Xu Q; Wang SY
Leuk Lymphoma; 2018 Jan; 59(1):196-203. PubMed ID: 28554272
[TBL] [Abstract][Full Text] [Related]
55. Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy.
Brkic S; Stivala S; Santopolo A; Szybinski J; Jungius S; Passweg JR; Tsakiris D; Dirnhofer S; Hutter G; Leonards K; Lischer HEL; Dettmer MS; Neel BG; Levine RL; Meyer SC
Leukemia; 2021 Oct; 35(10):2875-2884. PubMed ID: 34480104
[TBL] [Abstract][Full Text] [Related]
56. SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms.
Pandey G; Mazzacurati L; Rowsell TM; Horvat NP; Amin NE; Zhang G; Akuffo AA; Colin-Leitzinger CM; Haura EB; Kuykendall AT; Zhang L; Epling-Burnette PK; Reuther GW
Am J Hematol; 2024 Jun; 99(6):1040-1055. PubMed ID: 38440831
[TBL] [Abstract][Full Text] [Related]
57. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.
Parampalli Yajnanarayana S; Stübig T; Cornez I; Alchalby H; Schönberg K; Rudolph J; Triviai I; Wolschke C; Heine A; Brossart P; Kröger N; Wolf D
Br J Haematol; 2015 Jun; 169(6):824-33. PubMed ID: 25824483
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of vorinostat in a murine model of polycythemia vera.
Akada H; Akada S; Gajra A; Bair A; Graziano S; Hutchison RE; Mohi G
Blood; 2012 Apr; 119(16):3779-89. PubMed ID: 22408262
[TBL] [Abstract][Full Text] [Related]
59. Pro-Apoptotic Activity of Ruxolitinib Alone and in Combination with Hydroxyurea, Busulphan, and PI3K/mTOR Inhibitors in JAK2-Positive Human Cell Lines.
Szymańska J; Smolewski P; Majchrzak A; Cebula-Obrzut B; Chojnowski K; Treliński J
Adv Clin Exp Med; 2015; 24(2):195-202. PubMed ID: 25931349
[TBL] [Abstract][Full Text] [Related]
60. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW
Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]